Public perspective on potential treatment intervention harm in clinical trials—terminology and communication
This work provides a starting point on preferred terminology by patients and the public to describe potential harmful intervention effects. Whilst researchers have tried to seek agreement, public partners endorsed use of different terms for different situations. We highlight some key areas for improvement in public facing materials that are necessary to avoid miscommunication and incorrect perception of harm.
Authors
- Graeme MacLennan (ORCID: https://orcid.org/0000-0002-1039-5646)
- Marie Miller
- Dianne Murray (ORCID: https://orcid.org/0000-0003-4571-6531)
- Beatriz Goulão (ORCID: https://orcid.org/0000-0003-1490-7183)
- Anthony Myhill (ORCID: https://orcid.org/0009-0007-0146-8843)
- Victoria Cornelius (ORCID: https://orcid.org/0000-0002-0080-1065)
- Rachel Phillips (ORCID: https://orcid.org/0000-0002-3634-7845)
- Mike Melvin (ORCID: https://orcid.org/0009-0009-7603-6708)
- Dongquan Bi (ORCID: https://orcid.org/0000-0001-5234-302X)
- Peter Flockhart
- Laila Saeid
- Malak El-Askary
- Oluyemi Fagbemi
- Curie Freeborn
- Maria Giammetta
- Manos Kumar
- Shanice Thomas
- Noura El Masri
Institutions
- Queen Mary University of London (GB)
- University of Aberdeen (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Trials
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1186/s13063-024-08418-w
- Citations
- 2
- Primary Topic
- Pharmaceutical industry and healthcare
- Type
- article
- Field-Weighted Citation Impact
- 0.93
Funders
- National Institute for Health and Care Research
- Department of Health and Social Care
- Medical Research Council